A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies

NCT03338881 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business decision: no safety or efficacy concerns

Conditions

Advanced Solid Neoplasms
Lymphoma Neoplasms

Interventions

DRUG: [14C]-TAK-659
DRUG: TAK-659

Sponsor

Calithera Biosciences, Inc